TEVA

Teva Releases Q2 2026 Aide Memoire

Teva Sets Q2 2026 Aide Memoire Ahead of July 29 Results

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Teva issued its Q2 2026 Aide Memoire ahead of results due July 29, 2026. The document consolidates prior results, outlook, and third-party data to guide investors. Key focus will be guidance and debt management amid its shift toward biopharma and a robust generics slate.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Teva releases Q2 2026 Aide Memoire; results due July 29, 2026.</li><li>Q2 2026 results at 7:00 a.m. ET; conference call 8:00 a.m. ET.</li><li>Teva positions as innovative biopharma with a strong generics base.</li><li>Forward-looking statements caution investors on risks and indebtedness.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Teva Pharmaceutical Industries Ltd. (TEVA)</strong>: Subject of the release; Q2 2026 Aide Memoire and earnings in focus.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The piece is a pre-earnings disclosure detailing timing and scope of Teva&#039;s upcoming results, aligning with earnings-stage corporate communications.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q2 guidance and debt trajectory updates may drive TEVA shares.</li><li>Progress on biosimilars and complex generics could influence valuation.</li><li>If memo signals deteriorating cash flow or higher indebtedness, stock could weaken.</li><li>Conference call tone may shift investor sentiment on growth options.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 2026 Aide Memoire available on Teva Investors page.</li><li>Q2 2026 results expected July 29, 2026 at 7:00 a.m. ET.</li><li>Conference call on July 29, 2026 at 8:00 a.m. ET.</li><li>Teva positions as innovative biopharma with strong generics base.</li><li>Forward-looking statements section cautions risk factors including indebtedness.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral-to-bullish into the July 29 print, awaiting guidance and debt trajectory.</p>
  </section>
</section>


<article>
  <h2>Teva Releases Q2 2026 Aide Memoire</h2>

  <p>From Tel Aviv, Israel, June 18, 2026, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that its Q2 2026 Aide Memoire is available on the "Investors" page on its website. This release provides investors with public information ahead of Teva's second-quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day.</p>

  <p><a href="https://www.globenewswire.com/Tracker?data=WLSDJcDqH-WWBGBmaL8oZukjx9poWROlMMsVGwI43n8yl7pz7cianrGss0_h-AbzW6lZLJA0nuDPzA1tRggiyO33IBJuJQy5snUQW_jcPc0G6SlXsK2-ok_JpwVurLPbE_mRZ9LUA7ClYJsL7_DDGvZ5fRJaNt-w5fU-qXNe6LM=" rel="nofollow" target="_blank">Q2 2026 Aide Memoire</a></p>

  <p>Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources.</p>

  <section>
    <h3>Key Facts at a Glance</h3>
    <ul>
      <li><strong>Document:</strong> Q2 2026 Aide Memoire</li>
      <li><strong>Availability:</strong> On Teva's Investors page</li>
      <li><strong>Q2 2026 results release:</strong> Wednesday, <strong>July 29, 2026</strong> at <strong>7:00 a.m. ET</strong></li>
      <li><strong>Conference call:</strong> <strong>8:00 a.m. ET</strong> on the same day</li>
      <li><strong>Source basis:</strong> Public information previously disclosed by Teva and data from select independent sources</li>
    </ul>
  </section>

  <section>
    <h3>About Teva</h3>
    <p>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We <em>Are All In For Better Health</em>. To learn more about how, visit <a href="https://www.globenewswire.com/Tracker?data=4-hyhIIlh9sgQASbD6P3rgRf2m7zB1Vo-ZblmzJJrBIX7l-2RKw5nUfRBrciAcGTPNpGFLdmYPDdVSV_R793zarOrB1_whx7CmvdzNMVsvQCIGAo0ZMPbGz7jqIIjWpJ81Vj99aUJfukGYvjxXm5gLKdeX6exHnFJyzKud4HOq7u25IcFe3XEvDjOlTpW71SV97kssQTOnysyv7F9iGokEu1y4oi3yXQYDCrhem0lfzBB3YYVRBTiP8J7f_Y_ueqbPZCtoRhzcylKPf-DW7as-b9BeyqQJ7eP1AmedXCjkVWkvAOzh5epgTvBqyljoths1oJUVrXYRV75RRUJieRV_3jUcFOB5lcVr00MKz0FqRyxw4UaaOxVY-RT25d6uWsPBJ6-dhe5EyZiagAWfsZentzzoWF1LcM7D8fge26JaBbG67WBXgnFfpLWNavxMTqQfJWsYdR9pXTFIe9A0aWRxZod3zPk4uBnpefTjzUwpWQWrMIdtmQtQcGrh3GrrDxQlEgSveoC6tnkCzcsCfzJtI2UU3NWCcdO-coZRxoicCm3V74olFOitoSpyNjNAiPzt2WnLn8gYAg-Br0g5N54TJWU_fTZBPLmKBnJ7Cp1WsS8RQJ_yN_e8GvI5SU093f" rel="nofollow" target="_blank">www.tevapharm.com</a>.</p>
  </section>

  <section>
    <h3>Cautionary Note Regarding Forward-Looking Statements</h3>
    <p>This press release and the Aide Memoire document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Quarterly Report on Form 10-Q for the first quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</p>
  </section>

  <section>
    <h3>Media & Investor Relations Inquiries</h3>
    <p><strong>Teva Media Inquiries</strong><br />
    <a href="https://www.globenewswire.com/Tracker?data=EQQhvTl-0SORD-xyNgn_g8HdiGDxLQ1o5L6Ea3cOguJj29GKjFK7RefBy7PEZ1vNHSfIg9Wwn2pGr1SQ9yppQgSF1ztmisn9uOYVYa6nHINVN1clVtY620x9EoFi-FKfMzV0joOelmwPbSuc35DjUGGVUFuTIC7zma87mzzPsOM=" rel="nofollow" target="_blank"><strong>TevaCommunicationsNorthAmerica@tevapharm.com</strong></a></p>
    <p><strong>Teva Investor Relations Inquiries</strong><br />
    <a href="https://www.globenewswire.com/Tracker?data=EQQhvTl-0SORD-xyNgn_g5eSUo-BJ6sRNoRO72VYOfuaweBOHKTQM8Z6AwE7lD6fffcp2IHG4XaBisHKbqqDiXtIoYM52_i1B6sPeKwUH4k=" rel="nofollow" target="_blank"><strong>TevaIR@Tevapharm.com</strong></a></p>
  </section>

</article>

Teva issued its Q2 2026 Aide Memoire ahead of results due July 29, 2026. The document consolidates prior results, outlook, and third-party data to guide investors. Key focus will be guidance and debt management amid its shift toward biopharma and a robust generics slate.

Teva Releases Q2 2026 Aide Memoire

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Earnings

Related News